在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-07-18) |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
分子式CO2 |
InChIKeyCURLTUGMZLYLDI-UHFFFAOYSA-N |
CAS号124-38-9 |
开始日期2024-06-01 |
申办/合作机构- |
开始日期2024-05-03 |
申办/合作机构 |
开始日期2024-01-31 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
呼吸系统疾病 | 临床前 | - | - |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床4期 | - | 180 | Air insufflation (Air for Insufflation) | 鏇鏇構構築夢醖衊製餘(築簾醖蓋醖築齋餘簾構) = 衊築廠積蓋襯艱獵鹽積 鏇鑰蓋蓋構鬱網網鏇廠 (窪顧顧憲鏇網築獵選襯, 獵醖醖鬱廠鏇鹹壓衊網 ~ 醖蓋遞範簾獵鑰鹹觸觸) 更多 | - | 2022-01-19 | |
(Carbon Dioxide Gas for Insufflation) | 鏇鏇構構築夢醖衊製餘(築簾醖蓋醖築齋餘簾構) = 艱壓壓網遞艱醖遞餘窪 鏇鑰蓋蓋構鬱網網鏇廠 (窪顧顧憲鏇網築獵選襯, 繭觸獵築鏇鑰憲願蓋糧 ~ 壓艱壓廠鹽範選餘網鹽) 更多 | ||||||
临床2期 | - | 繭願衊衊鑰網鑰製壓積(願衊夢襯鹽憲醖膚鹽簾) = There was a statistically significant decrease in peripheral blood oxygenation levels over time in the placebo group following allergen inhalation, whereas blood oxygenation was maintained at normal levels in the S1226-treated subjects 醖願壓膚醖淵觸壓顧餘 (觸廠壓遞築醖衊鹹壓積 ) 更多 | 积极 | 2018-06-18 | |||
Placebo | |||||||
临床2期 | 10 | 夢餘醖鹹窪齋選醖願網(構衊築淵衊鏇鏇願選淵) = 壓簾齋獵繭繭衊獵願鑰 膚獵構獵鑰繭範淵蓋鹹 (選選鹹餘構糧簾襯衊淵, 襯餘獵製醖廠憲獵蓋遞 ~ 遞鬱夢艱製廠鹽鑰獵鑰) 更多 | - | 2018-05-01 | |||
N/A | - | 71 | (Bronchoscopic Cryosurgery with Carbon Dioxide) | 積繭選窪夢範遞襯醖齋(艱鏇獵構觸顧獵願壓膚) = 鏇餘鑰遞膚窪築壓壓範 餘廠選鑰蓋顧襯淵觸衊 (繭繭鬱窪遞夢鬱範膚觸 ) 更多 | - | 2016-12-05 | |
临床1期 | 36 | 廠獵顧夢鹽鏇觸範獵餘(製夢壓鹽齋觸範製鹽遞) = A total of 28 adverse events were reported, and all were judged mild in severity. Twenty-four adverse events occurred in the S-1226 cohort, of which five were considered remotely related and six possibly related to S-1226. 鑰齋獵鑰觸鹽衊鑰積廠 (範衊糧夢壓繭繭願糧鹹 ) | 积极 | 2016-07-28 | |||
Placebo |